Li Tao, PhD, discusses early US uptake of twice-yearly lenacapavir, faster prescription-to-injection timelines, and how ACA coverage milestones tracked with zero cost sharing and HIV diagnoses.
|Articles|July 27, 2017
Mother-to-Child Transmission of HIV Remains a Significant Burden
Author(s)Contagion Editorial Staff
Lynne Mofenson, MD, shares an update on the health burden of mother-to-child transmission (MTCT) of HIV.
Advertisement
Lynne Mofenson, MD, Senior HIV Technical Advisor, Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, United States shares an update on the health burden of mother-to-child transmission (MTCT) of HIV.
Interview Transcript (slightly modified for readability):
“HIV remains a significant burden in children. There are about 1.4 million HIV-infected women who give birth every year. We have managed to decrease mother-to-child transmission significantly. In 1999, half a million children were born infected [with HIV] that year alone. With our current interventions, however, in 2015 [that number] had decreased to 150,000 infected children. That sounds good, but that [number still equates to] 400 infected children born every day, and so we still have a way to go."
Advertisement
Related to this article
Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
Dr. Reddy’s generic twice-yearly lenacapavir received FDA tentative approval for HIV PrEP. It is expected to cost $40 a year in 120 low- and middle-income countries (LMICs), with first supplies due by the end of 2026.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
The Peggy Lillis Foundation's CEO and Co-founder Christian Lillis discusses the organization's initiatives for C diff month, and offers a glimpse of the upcoming Scientific Symposium they are hosting next week.
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
David Altarac, MD, discusses 2025 SENTRY data, ESBL considerations in empiric therapy, and where ceftobiprole fits alongside ceftaroline in S aureus bacteremia.
Advertisement
Advertisement